High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings

Alexandra Martin [a], Alexandre Storto [b,c], Quentin Le Hingrat [b,c], Gilles Collin [b,c], Barbara André [a], Allison Mallory [a], Rémi Dangla [a], Diane Descamps [b,c], Benoit Visseaux [b,c,*], Olivier Gossner [d]

[a] Stilla Technologies, Villejuif, France
[b] Université de Paris, Assistance Publique – Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France
[c] UMR 1137-IAME, DeSCID: Decision Sciences in Infectious Diseases control and care, INSERM, Université de Paris, Paris, France
[d] CNRS- CREST, Ecole Polytechnique, Palaiseau, France and London School of Economics, London, United Kingdom

ARTICLE INFO

ABSTRACT

Background: Worldwide demand for SARS-CoV-2 RT-PCR testing is still high as testing remains central to follow the disease spread and vaccine efficacy. Group testing has been proposed as a solution to expand testing capabilities but sensitivity concerns may limit its impact on the management of the pandemic. Digital PCR (RT-dPCR) has been shown to be highly sensitive and could help by providing larger testing capabilities without compromising sensitivity.

Methods: We implemented RT-dPCR based COVID-19 group testing on a commercially available system and assay (naica® system from Stilla Technologies) and investigated the sensitivity of the method in real life conditions of a university hospital in Paris, France, in May 2020. We tested the protocol in a direct comparison with reference RT-PCR testing on 448 samples split into groups of 8, 16 and 32 samples for RT-dPCR analysis.

Results: Individual RT-PCR testing identified 25/448 positive samples. Using 56 groups of 8, RT-dPCR identified 23 groups as positive, corresponding to 26 positive samples by individual PCR (positive percentage agreement 95.2% [95% confidence interval: 76.2–99.9%]) and including 2 samples not detected by individual RT-PCR but confirmed positive by further investigation. 15 of 28 groups of 16 tested positive, corresponding to 25 positive samples by individual PCR (positive percentage agreement 87.5% [95% confidence interval: 61.7–98.4%]). 14 groups of 32 were fully concordant with individual PCR testing but will need to be confirmed on larger datasets.

Conclusions: Our proposed approach of group testing by digital PCR has similar diagnostic sensitivity compared to individual RT-PCR testing for group up to 16 samples. This approach reduces the quantity of reagent needed by up to 80% while reducing costs and increasing capabilities of testing up to 10-fold.

1. Introduction

As contact tracing and close epidemiological follow-up of COVID-19 remains the cornerstones of the disease control measures in most countries of the Northern hemisphere, many of them have implemented extensive monitoring policies to prevent and control the apparition of new clusters. These policies, requiring important testing capabilities, were exemplified in Wuhan where all 11 million citizens were tested in 10 days during May 2020. The start of the vaccine campaigns will also need close follow-up to check vaccination efficacy. Thus, scaling up and maintaining large testing capacities worldwide remains a challenge,

with high cost, limited reagents and scarcity of testing equipment or laboratory staff likely to remain limitations.

Group testing or pooling, first suggested by Dorfman in 1943, is a protocol through which individual samples are combined together before running the test[1]. The advantage of the method is an overall saving in the number of tests required to screen a given population[2], and thereby an increase in testing capabilities for fixed reagent and instrumentation availability. Savings depend on key parameters such as the disease prevalence and the group size. Group testing protocols using real-time reverse-transcriptase PCR (RT-PCR) have been evaluated and implemented for COVID-19 screening around the world in several

---

experiments using RT-PCR detection techniques, notably in Israel, Germany, California, Nebraska, NY State, and Italy[3–9].

Although these studies show that positive individuals can be detected in pooled samples, it is often with a decreased sensitivity due to dilution and perhaps inhibition effects[3,5,7,9]. This can prevent weakly-positive specimens from being detected in group samples[3,8]. Concerns about the sensitivity of group testing have been raised by French medical authorities, leading to a negative recommendation on their use in France[10]. On the other hand, on the 18th of July 2020, the US Food and Drug Administration (FDA) authorized a first diagnostic test for use with pooled samples containing up to 4 individual swab specimens[11].

Digital PCR (or RT-dPCR) is known for its higher sensitivity over classical RT-PCR[12,13], including for SARS-CoV-2 detection[15–17], and resistance to PCR inhibitors[14].

In this study we propose a novel group testing protocol using a commercially available SARS-CoV-2 RT-dPCR assay and compare empirically the positive and negative percentage agreement of individual RT-PCR with group testing by RT-dPCR for three group sizes of 8, 16 and 32 samples. Discrepancies were further analyzed using individual RT-dPCR and discrepancy RT-PCR. We find that, in our condition, group testing by RT-dPCR performed with similar sensitivity to the reference individual RT-PCR testing for groups of 8 and 16.

2. Material and methods

2.1. Summary of the method of the comparative study

Overall, 448 patient samples were tested for SARS-CoV-2 by i) individual RT-PCR, ii) RT-dPCR in 56 groups of 8 samples, iii) RT-dPCR in 28 groups of 16 samples and iv) RT-dPCR in 14 groups of 32 samples. In case of discordance between the results of individual RT-PCR testing and group testing in RT-dPCR, samples were re-analyzed individually by RT-dPCR, the gold-standard RT-PCR and a confirmatory RT-PCR assay. The whole protocol is illustrated in Fig. 1.

2.2. Specimens collection, storage and pooling

Nasopharyngeal swabs of 448 symptomatic patients screened for COVID-19 of the Bichat university hospital (Paris, France) between May 6th and May 26th, 2020 were included. Individuals included in the study were all either hospitalized or assessed in the emergency department. All samples were collected in universal transport medium (UTM) (Viro-cult®, Sigma-Aldrich, Saint-Louis, USA, or eSwab™, Copan, Brescia, Italy) and tested, within 15 h maximum upon collection, for SARS-CoV-2 detection by RT-PCR (Cobas SARS-CoV-2 test, Roche, Risch-Rotkreuz, Switzerland). Remaining volumes were kept at +5 °C and, if above 600 μL, systematically included in the group testing analysis in the same 24 h. Thus, 125 μL of each included specimen was randomly mixed with seven others to generate 56 groups of 8 specimens with a final volume of 1 mL per group. The remaining volume of transport medium was stored at +5 °C. According to the current French ethical laws, samples used in the current study were only included after the completion of all analysis required for the patient's care.

2.3. Detection of SARS-CoV-2 by routine individual RT-PCR testing

All 448 specimens were analyzed individually on a Cobas® 6800 system (Roche, Switzerland) for COVID-19 screening using the Cobas® SARS-CoV-2 Test kit following manufacturer's instruction. Within a maximum storage at +5 °C of 11 days, except for Sample_25,659 tested at 20 days, samples which had different results for RT-PCR and RT-dPCR were reassessed on the Cobas® 6800 system. In case of low remaining amounts of transport medium, the nasal swabs were vortexed once more into the remaining transport medium diluted 1 to 10 with new transport medium.

2.4. Extraction of total nucleic acids on grouped samples

All nucleic acids extractions for RT-dPCR assays were performed on a MagNA Pure LC 2.0 (Roche) using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche) following manufacturer's instructions. For all sample groups, a total volume of 1 mL was used. For individual samples, 200 μL was diluted with 800 μL of buffer before extraction. Nucleic acids were eluted from 1 mL to 50 μL of the elution buffer provided with the kit and stored at +5 °C for a maximum of 12 h before analysis.

2.5. Preparation of groups of 16 and 32 individuals

After extraction of the 56 groups of 8 specimens (P8 groups) and

Fig. 1. Schematic of the structure of the comparative study.

prior to viral testing by RT-dPCR, 28 groups of 16 individual samples (P16 groups) were obtained by mixing 15 μL of 2 P8 groups and 14 groups of 32 (P32 groups) were obtained by mixing 10 μL of 2 P16 groups.

2.6. Detection of SARS-CoV-2 by grouped RT-dPCR testing using the naica® system

SARS-CoV-2 titration of the grouped samples by RT-dPCR was performed on the naica® system (Stilla Technologies, France) within the next three hours after extraction, using the COVID-19 Multiplex Digital PCR Detection Kit (Stilla Technologies, France/Apexbio, China), allowing detection of the *N* gene, the *ORF1ab* gene and an internal control, as recommended by the manufacturer and described in S1-Supplementary Materials. The naica® system performs digital PCR by partitioning the samples into arrays of up to 30 000 micro-droplets called droplet crystals using a microfluidic Sapphire Chip and two dedicated instruments (Geode and Prism3). The readout has 3 fluorescence channels. The naica® system is for Research-Use Only.

2.7. Individual confirmatory testing for SARS-CoV-2 by RT-PCR and RT-dPCR

In case of discrepancies between individual RT-qPCR and grouped RT-dPCR, RT-dPCR results were confirmed by extracting and retesting individually each sample of the group by RT-dPCR and RT-qPCR as previously described and with a third method, the RealStar® SARS CoV-2 RT-PCR Kit (Altona Diagnostics, Germany)[18].

2.8. Limit of blank and limit of detection of RT-dPCR

The Limit of Blank for SARS-CoV-2 detection using the group testing approach and the Limit of Detection were evaluated on-site. The methods and results are disclosed in the S2- and S3-Supplementary Materials.

3. Results

3.1. Cohort description from routine RT-PCR testing

Using routine RT-PCR testing, 25 samples were identified as positive out of the 448 samples tested, corresponding to an average test positivity rate of 5.5%. The average Ct value was of 30.0 and 27.3 for the *E* gene and *ORF* gene respectively, with minimum values of 16.5 and 16.3 and maximum values of 38.7 and >40 (not detected) (Fig. 2).

3.2. Results from grouped RT-dPCR testing

All results for the detection of SARS-CoV-2 by RT-dPCR for grouped testing are presented in Table 1. Because testing was performed systematically as samples came in the laboratory, the groups contain variable numbers of RT-PCR positive samples ("RT-PCR+" samples): 35 with 0, 18 with 1 and 3 with more than 1 RT-PCR+ samples. For the largest group size of 32 samples, only 2 P32 groups had no RT-PCR+ samples.

3.3. Detailed results for RT-dPCR in groups of 8

The results, detailed in Tables 1 and 2, are in concordance with the reference individual RT-PCR testing for 52 groups (corresponding for 416 samples), including 32 RT-PCR negative groups and 20 containing at least one RT-PCR+ sample, resulting in a positive and negative percentage agreement at 95.2% (95% confidence interval (95CI): 76.2–99.9) and 91.4% (95CI: 76.9–98.2). For the remaining 4 groups, three RT-PCR negative groups tested positive by RT-dPCR ("PCR-/dPCR+" discordances – group IDs: P8_20, P8_28 and P8_39, cf Table 3 and supplementary material 4) and one RT-PCR+ positive group was found negative by RT-dPCR (PCR+/dPCR- discordance – group ID: P8_02). The Ct values for the sample associated with the PCR+/dPCR-discordance (Sample 25,659) were 34 and 32.3 for the *E* gene and *ORF1ab* with the Cobas® SARS-CoV-2 assay, respectively. Of note, out of the 8 individual samples with Ct > 35 for the *E* gene, 6 ended up to be


Fig. 2. Distribution of Ct values for the E gene and ORF gene, as measured using individual reference RT-PCR with Cobas® 6800 SARS-CoV-2 assay, for the 25 positive samples.

Table 1

Distribution of the samples identified as positive by the routine RT-PCR method (Cobas® SARS-CoV-2 assay) in the groups of 8, 16 and 32 and corresponding RT-dPCR detection of SARS-CoV-2 in the groups.

Number of RT-PCR positive sample(s) in the group	Results for P8 groups *(in number of P8 groups)*			Results for P16 groups *(in number of P16 groups)*			Results for P32 groups *(in number of P32 groups)*		
	Total	*dPCR -*	*dPCR +*	*Total*	*dPCR -*	*dPCR +*	*Total*	*dPCR -*	*dPCR +*
0	35	32	3	12	11	1	2	2	0
1	18	1	17	10	2	8	6	0	6
2	2	0	2	4	0	4	3	0	3
3	1	0	1	1	0	1	1	0	1
4	0	0	0	1	0	1	1	0	1
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	1	0	1
Total	56	33	23	28	13	15	14	2	12

Table 2

Confusion matrix for P8*, 16 and 32 groups of samples.*

Confusion matrix *Results are given in number of groups*	Expected negatives (RT-PCR)	Expected positives (RT-PCR)	*Total*
P8 groups			
Negatives in RT-dPCR	32	1	*33*
Positives in RT-dPCR	3	20	*23*
Total	*35*	*21*	*56*
P16 groups			
Negatives in RT-dPCR	11	2	*13*
Positives in RT-dPCR	1	14	*15*
Total	*12*	*16*	*28*
P32 groups			
Negatives in RT-dPCR	2	0	*2*
Positives in RT-dPCR	0	12	*12*
Total	*2*	*12*	*14*

Table 3

Detailed results of confirmatory testing for COBAS-/dPCR+ discordances by individual reassessment using both RT-dPCR and RT-PCR (Altona and Cobas®). NT = "Not tested". ND= "Not detected".

———

———

the only positive sample in a P8 group and all were detected positive by RT-dPCR. The highest detected Ct value for the *E* gene was 38.7 with a not detected *ORF1ab* gene.

3.4. Detailed results for RT-dPCR in groups of 16

The results, detailed in Tables 1 and 2, are in concordance with individual RT-PCR testing for 25 groups (corresponding to 400 samples), including 11 RT-PCR- and 14 RT-PCR+ groups, corresponding to a positive and negative percent agreement at 87.5% (95CI: 61.7–98.4%) and 91.7% (95CI: 61.5–99.8%). Among the three groups with discordant results, one presented a PCR-/dPCR+ discordance and 2 PCR+/dPCR- discordances. Of note, out of the 8 individual samples with Ct > 35 for the *E* gene, 5 ended up to be the only positive sample in a P16 group. Two of these groups are responsible for the 2 PCR+/dPCR- discordances. The *E* gene and *ORF1ab* Ct values for these 2 samples were of [36.7; >40 (not detected)] and [36.3; 34.2], while the highest Ct values for a detected single positive sample were [38.3; >40].

3.5. Detailed results for RT-dPCR in groups of 32

The results are in concordance with individual RT-PCR testing for all 14 groups (corresponding for 448 samples) and are depicted in Tables 1 and 2. Out of the 8 individual samples with Ct > 35 for the *E* gene, 3 ended up to be the only positive sample in a P32 group. All such 3 P32 groups tested positive by RT-dPCR. The highest corresponding detected Ct values for the *E* gene and *ORF1ab* is of [36.7; >40].

Investigation of the discordances and correlation between RT-dPCR measurements and Ct values

Investigations of the discordances are depicted in S4-Supplementary Materials. The correlation between RT-dPCR measurement and Ct values is presented in S5-Supplementary Materials.

4. Discussion

In this work, we assessed the agreement with individual RT-PCR of group testing combined with digital PCR for SARS-CoV-2 detection. Three different group sizes were investigated using a commercially available digital PCR assay, the COVID-19 Multiplex Digital PCR Detection Kit (Stilla Technologies, France/Apexbio, China). This assay demonstrated a low limit of blank (at 2 and 0 positive droplets per PCR for *N* and *ORF1ab* genes, respectively) and limit of detection (LoD) (at 77 copies/mL, corresponding to 8 copies/reaction, versus 170 copies/mL, corresponding to 34 copies/reaction, for the Altona RT-PCR assay used for direct comparison). This LoD is lower than most estimation for WHO and other reference RT-PCR assays typically ranging between 5 and 500 copies/PCR[19,20] and between 625 and 1000 copies/mL in the same extraction conditions[18,19].

For our analysis, we proposed a protocol of group screening performed by RT-dPCR with secondary individual re-testing of positive groups as illustrated in S6-Supplementary Materials. We assessed this protocol by testing in real-life condition 448 consecutive samples grouped by 8, 16 and 32 samples. We observed similar sensitivity with pooled RT-dPCR than with individual RT-PCR testing for groups of 8 samples. According to discrepancy analysis, 23 groups of 8 samples tested positive with RT-dPCR, allowing to subsequently identify 26 true positive samples when only 25 samples were identified through individual RT-PCR testing. Moreover, among the latter 25 samples, one was a non-conclusive sample (not detected by the confirmatory RT-PCR assay) associated to a PCR+/dPCR- discrepancy. Finally, this corresponds to $a + 8\%$ improvement in sensitivity, using the discrepancy analysis as the final result and excluding the non-conclusive sample. Two among the three samples associated with PCR-/dPCR+ discordances were confirmed as positive by the confirmatory RT-PCR assay (Altona). To note that, in case of insufficient remaining sample volume for discrepancy analysis, it had to be diluted 1 to 10 with new transport media. This could have an impact on sensitivity of our discrepancy analysis. Along with our LoD assessment, these results underline the RT-dPCR capacity to detect lower viral loads than RT-PCR. Low viral loads could correspond to either very early presentation, before the viral load peak, or to patients detected very lately after the disease onset. If any doubt exists, those situations will have to be discussed and investigated cautiously by physicians and virologists, as done for individual RT-PCR.

Grouped testing by RT-dPCR has a high positive agreement to individual RT-PCR testing for a group size of 16 samples. 15 groups of 16 samples tested positive by RT-dPCR and included a total of 24 true positive samples (22 RT-PCR+ and 2 PCR-/dPCR+ samples). Excluding the non-conclusive sample from the 25 RT-PCR positive samples, this leads to an improvement of 4% in sensitivity by dPCR in group of 16 compared to individual RT-PCR and using discrepancy analysis as the

final result. However, 2 RT-PCR+ groups tested negative with RT-dPCR, likely explained by high Ct values of the single positive sample included in each of these groups.

Testing in the 14 groups of 32 samples by RT-dPCR has 100% concordance with the reference RT-PCR testing. As only 14 groups, including only 2 RT-PCR negative groups, we are careful in drawing conclusion for groups of 32. These are still promising results, including 448 individuals, although additional testing would be desirable.

An alternative and even more cost-effective group testing protocol could be to perform the re-testing steps using RT-PCR with Cobas or Altona assays. In these protocols, the agreement with individual RT-PCR becomes dependent on the RT-PCR kit used, leading to potential discrepancies with RT-dPCR as observed in our results for groups of 8 samples.

Our study presents several limitations. As we performed repeat and discrepancy analysis testing up to 20 days of +5 °C storage, this may have decreased their sensitivity despite the use of viral transport media dedicated to nucleic acid conservation. Another limitation is the use of a limited number of pools, despite the inclusion of 448 patients, especially for the pools including 32 samples. Larger studies should be needed to confirm these findings. Overall, our data indicates that COVID-19 group testing combined with digital PCR for large group sizes of 8 and 16 samples has strong positive and negative agreements with individual RT-PCR testing. In several pools, the RT-dPCR was able to detect positive samples, not detected by the individual RT-PCR but further confirmed by the discrepancy RT-PCR assay. The gain in sensitivity of the proposed method is likely due to a combination of *i)* a concentration effect due to performing the pooling prior extraction and performing the extraction step from a large volume of 1 mL of pooled transport medium and *ii)* the intrinsic superior sensitivity of digital PCR compared to RT-PCR, as demonstrated previously for SARS-CoV-2[15–17] and other viruses[13, 21] detection.

Below standard sensitivity is one of the main reasons why group testing has not been widely adopted for COVID-19 testing, whilst research groups have advocated for its implementation as a solution to the world-wide demand for tests and reagent shortage[2-9]. The current study suggests that high sensitivity can be achieved in group testing using digital PCR instead of RT-PCR in the first group screening step. Group testing by RT-PCR is known to enable large-scale, low cost patient screening with minimum reagent consumption[1-3]. Digital PCR has higher costs (typical range of 30 € to 50 € per test, varies between test settings) than standard RT-PCR (typical range of 10 € to 20 € per test, varies between test settings), but significant reagent and cost savings can also be achieved with group testing by digital PCR. Savings will depend on the positivity rate, the group size and the cost of dPCR testing. For test positivity rates below 1% and assuming digital PCR as 2 to 4 times more expensive than individual RT-PCR test, cost reductions of at least 40% and reagents savings of at least 70% are achievable. In similar conditions, but for a test positivity rate of 5%, cost savings will be between 16% and 40% depending on the actual cost of testing by digital PCR. A detailed analysis of reagent and cost savings is given in the S7-Supplementary Materials.

Consequently, group testing by digital PCR can indeed provide large-scale, low cost patient screening with minimum reagent consumption without sacrificing sensitivity. Limitations are 1) that test positivity rates should be low, ideally below 1% for the large group sizes contemplated here, 2) that it requires laboratories trained in molecular assays to implement the manual pooling protocols and 3) automated solutions, including deconvolution algorithms to confirm positives and appropriate IT infrastructure, are needed to support high-volume testing and timely results.

Group testing can be used in various context where testing is not widely available due to testing capacity, economics, or reagent access constraints and where SARS-CoV-2 prevalence is low. In countries where the pandemic is not yet under control or could re-emerge, enhancing testing capacity is essential to control COVID-19 expansion. Increasing

the range of people tested amongst contacts with positive cases, but also periodic testing of population in frequent contact with others (e.g. nurses, transportation workers, clerks, etc.…) as well as in fragile populations such as nursing homes, or vaccination follow-up, can be part of future strategies against COVID-19 while allowing a relaxation of social distancing measures at the same time. Group testing can help in all of these situations.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcv.2021.104895.

References

[1] R. Dorfman, The detection of defective members of large populations, Ann. Math. Stat. 14 (1943) 436–440.

[2] C. Gollier, O. Gossner, Group Testing against COVID-19. 2020–04Working Papers, Center for Research in Economics and Statistics, 2020.

[3] I. Yelin, N. Aharony, E. Shaer Tamar, A. Argoetti, E. Messer, D. Berenbaum, E. Shafran, A. Kuzli, N. Gandali, O. Shkedi, T. Hashimshony, Y. Mandel-Gutfreund, M. Halberthal, Y. Geffen, M. Szwarcwort-Cohen, R Kishony, Evaluation of COVID-19 RT-qPCR test in multi-sample pools, Clin. Infect. Dis. (2020) ciaa531.

[4] Schmidt M., Hoehl S., Berger A., Zeichhardt H., Hourfar K., Ciesek S., Seifried E. 2020. FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity. medRxiv 2020.04.28.20074187.

[5] Anderson C., Castillo F., Koenig M., Managbanag J. 2020. Pooling nasopharyngeal swab specimens to increase testing capacity for SARS-CoV-2. bioRxiv 2020.05.22.110932.

[6] C.A. Hogan, M.K. Sahoo, B.A. Pinsky, Sample pooling as a strategy to detect community transmission of SARS-CoV-2, JAMA 323 (2020) 1967.

[7] B. Abdalhamid, C.R. Bilder, E.L. McCutchen, S.H. Hinrichs, S.A. Koepsell, P. C. Iwen, Assessment of specimen pooling to conserve SARS CoV-2 testing resources, Am. J. Clin. Pathol. 153 (2020) 715–718.

[8] S.B. Griesemer, G. Van Slyke, K St. George, Assessment of Sample Pooling for Clinical SARS-CoV-2 Testing, Microbiology, 2020 preprint.

[9] S. Lohse, T. Pfuhl, B. Berkó-Göttel, J. Rissland, T. Geißler, B. Gärtner, S.L. Becker, S. Schneitler, S. Smola, Pooling of samples for testing for SARS-CoV-2 in asymptomatic people, Lancet Infect. Dis. (2020). S1473309920303625.

[10] HCSP, Coronavirus SARS-CoV-2 : Poolage Des Tests RT-PCRRapport De l'HCSP, Haut Conseil de la Santé Publique, Paris, 2020.

[11] HCSP, Coronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing, FDA. FDA., 2020.

[12] M.C. Strain, S.M. Lada, T. Luong, S.E. Rought, S. Gianella, V.H. Terry, C.A. Spina, C.H. Woelk, D.D. Richman, Highly precise measurement of HIV DNA by Droplet digital PCR, PLoS ONE 8 (2013) e55943.

[13] J.-.T. Huang, Y.-.J. Liu, J. Wang, Z.-.G. Xu, Y. Yang, F. Shen, X. Liu, X. Zhou, S.-. M. Liu, Next generation digital PCR measurement of hepatitis B virus copy number in formalin-fixed paraffin-embedded hepatocellular carcinoma tissue, Clin. Chem. 61 (2015) 290–296.

[14] T.C. Dingle, R.H. Sedlak, L. Cook, K.R. Jerome, Tolerance of Droplet-digital PCR vs real-time quantitative PCR to inhibitory substances, Clin. Chem. 59 (2013) 1670–1672.

[15] F. Yu, L. Yan, N. Wang, S. Yang, L. Wang, Y. Tang, G. Gao, S. Wang, C. Ma, R. Xie, F. Wang, C. Tan, L. Zhu, Y. Guo, F. Zhang, Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients, Clin. Infect. Dis. (2020) ciaa345.

[16] L. Dong, J. Zhou, C. Niu, Q. Wang, Y. Pan, S. Sheng, X. Wang, Y. Zhang, J. Yang, M. Liu, Y. Zhao, X. Zhang, T. Zhu, T. Peng, J. Xie, Y. Gao, D. Wang, Y. Zhao, X. Dai, X. Fang, Highly Accurate and Sensitive Diagnostic Detection of SARS-CoV-2 by Digital PCR, Public and Global Health, 2020 preprint.

[17] T. Suo, X. Liu, J. Feng, M. Guo, W. Hu, D. Guo, H. Ullah, Y. Yang, Q. Zhang, X. Wang, M. Sajid, Z. Huang, L. Deng, T. Chen, F. Liu, K. Xu, Y. Liu, Q. Zhang, Y. Liu, Y. Xiong, G. Chen, K. Lan, Y Chen, ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens, Emerg Microbes Infect. (2020) 1–30.

[18] B. Visseaux, Q. Le Hingrat, G. Collin, V. Ferré, A. Storto, H. Ichou, D. Bouzid, N. Poey, E. de Montmollin, D. Descamps, N Houhou-Fidouh, Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection, J. Clin. Virol. 129 (2020), 104520.

[19] B. Visseaux, Q. Le Hingrat, G. Collin, D. Bouzid, S. Lebourgeois, D. Le Pluart, L. Deconinck, F.-.X. Lescure, J.-.C. Lucet, L. Bouadma, J.-.F. Timsit, D. Descamps, Y. Yazdanpanah, E. Casalino, N. Houhou-Fidouh, Emergency Department Influenza Study Group, Evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection, J. Clin. Microbiol. (2020) 58.

[20] C.B.F. Vogels, A.F. Brito, A.L. Wyllie, J.R. Fauver, I.M. Ott, C.C. Kalinich, M. E. Petrone, A. Casanovas-Massana, M.C. Muenker, A.J. Moore, J. Klein, P. Lu, A. Lu-Culligan, X. Jiang, D.J. Kim, E. Kudo, T. Mao, M. Moriyama, J.E. Oh, A. Park, J. Silva, E. Song, T. Takehashi, M. Taura, M. Tokuyama, A. Venkataraman, O.-. E. Weizman, P. Wong, Y. Yang, N.R. Cheemarla, E. White, S. Lapidus, R. Earnest, B. Geng, P. Vijayakumar, C. Odio, J. Fournier, S. Bermejo, S. Farhadian, C. Dela Cruz, A. Iwasaki, A.I. Ko, M.-.L. Landry, E.F. Foxman, N.D Grubaugh, Analytical Sensitivity and Efficiency Comparisons of SARS-COV-2 qRT-PCR assays, Infectious Diseases (except HIV/AIDS), 2020. Preprint.

[21] R.K. Gupta, S. Abdul-Jawad, L.E. McCoy, H.P. Mok, D. Peppa, M. Salgado, J. Martinez-Picado, M. Nijhuis, A.M.J. Wensing, H. Lee, P. Grant, E. Nastouli, J. Lambert, M. Pace, F. Salasc, C. Monit, A.J. Innes, L. Muir, L. Waters, J. Frater, A. M.L. Lever, S.G. Edwards, I.H. Gabriel, E. Olavarria, HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation, Nature 568 (2019) 244–248.